In June 2026, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Wegovy, a once-daily oral semaglutide tablet, for weight management. This approval marks the first time a GLP-1 receptor agonist tablet has been authorized in the UK, offering a new option for adults with obesity or overweight conditions (BMI of 30 or above, or those with a BMI of 27 to 30 who have at least one weight-related health condition, such as high blood pressure). Clinical trials have demonstrated that participants can achieve an average weight loss of approximately 14% over 64 weeks when combined with a reduced-calorie diet and increased physical activity. The medication is currently available for NHS funding. The cost of the medication has not yet been finalized, but it is anticipated to be more affordable than the injectable version, which typically costs between £30 and £300 per month, depending on the dose and length of prescription.
The introduction of Wegovy is seen as a significant development in the UK's efforts to address obesity, a condition affecting a substantial portion of the adult population. Health experts hope that the availability of this new treatment will provide individuals with additional tools to manage their weight effectively.
As of July 2026, Wegovy is available for private prescription in the UK. Patients interested in the medication should consult with their healthcare providers to determine if it is appropriate for their individual health needs.